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Abstract 34	
Macrophages are key regulators of fibrosis development and resolution. Elucidating the 35	
mechanisms by which they mediate this process is crucial for establishing their therapeutic 36	
potential.  Here, we use experimental models of liver fibrosis to show that deficiency of the 37	
scavenger receptor, stabilin-1, exacerbates fibrosis and delays resolution during the 38	
recovery phase. We detected a subset of stabilin-1+ macrophages which were induced at 39	
sites of cellular injury close to the hepatic scar in mouse models of liver fibrosis and in 40	
human liver disease.  Stabilin-1 deficiency abrogated malondialdehyde-LDL (MDA-LDL) 41	
uptake by hepatic macrophages and was associated with excess collagen III deposition. 42	
Mechanistically, the lack of stabilin-1 led to elevated intrahepatic levels of the pro-fibrogenic 43	
chemokine CCL3 and an increase in GFAP+ fibrogenic cells. Stabilin-1-/- macrophages 44	
demonstrated a pro-inflammatory phenotype during liver injury and the normal induction of 45	
Ly6Clo monocytes during resolution was absent in stabilin-1 knockouts leading to 46	
persistence of fibrosis. Human stabilin-1+ monocytes efficiently internalised MDA-LDL and 47	
this suppressed their ability to secrete CCL3 suggesting that loss of stabilin-1 removes a 48	
brake to CCL3 secretion.	 In support of this, studies with cell lineage specific knockouts 49	
revealed that stabilin-1 expression in myeloid cells is required for the induction of this novel 50	
subset of macrophages and that increased fibrosis occurs in their absence. This study 51	
demonstrates a new regulatory pathway in fibrogenesis in which a macrophage scavenger 52	
receptor protects against organ fibrosis by removing fibrogenic products of lipid 53	
peroxidation. Thus stabilin-1+ macrophages shape the tissue microenvironment during liver 54	
injury and healing. 55	
 56	
 57	
 58	
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 59	
Significance Statement 60	
Organ fibrosis is a major cause of global morbidity and mortality. It is driven by chronic 61	
inflammation and associated oxidative stress with depletion of cellular antioxidant defenses.    62	
We demonstrate a novel mechanism in which the evolutionarily conserved receptor stabilin-63	
1 on tissue-infiltrating macrophages provides a second-line defense to prevent tissue 64	
damage from oxidative stress.   Stabilin-1+ monocytes take up malondialdehyde-LDL (MDA-65	
LDL), a major product of oxidative lipid peroxidation, to form ceroid-laden macrophages.  66	
Through the uptake of MDA-LDL, stabilin-1 suppresses production of the pro-fibrogenic 67	
chemokine CCL3 and prevents excessive collagen deposition in experimental models of 68	
liver fibrosis.  We propose that macrophage stabilin-1 is a critical defense against oxidative 69	
tissue damage and thereby maintains tissue homeostasis.  70	
 71	
/body 72	
Introduction 73	
Liver fibrosis is driven by extracellular matrix (ECM) deposition by activated myofibroblasts, 74	
the majority of which arise from the hepatic stellate cell (HSC) (1). The accumulation of an 75	
ECM rich in fibrillar collagens I and III, causes architectural distortion which leads to organ 76	
dysfunction and portal hypertension. Consequently, identifying pathways which regulate the 77	
deposition and resolution of fibrillar collagen is vital to developing new treatments for 78	
chronic liver disease. Products of oxidative stress, such as oxidised-low density lipoproteins 79	
(oxLDLs), can directly activate HSC to an ECM-producing state thereby driving fibrogenesis 80	
(2, 3). In addition to HSCs, other non-parenchymal cells, contribute to the regulation of liver 81	
fibrosis. Hepatic sinusoidal endothelial cells (HSEC), which lie in close proximity to HSCs, 82	
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play an important role in maintaining HSC quiescence (4), and macrophages play a critical 83	
role in fibrosis progression, tissue remodelling and resolution (5).   84	
Stabilin-1, also known as CLEVER-1 (gene name Stab1), is a highly conserved 85	
transmembrane glycoprotein that is expressed by sinusoidal endothelium, and sub-86	
populations of macrophages (6).  Previous studies have demonstrated multiple stabilin-1 87	
ligands including oxLDL (7), the ECM glycoprotein osteonectin (8) and placental lactogen 88	
(9) suggesting that stabilin-1 functions as a homeostatic scavenger receptor. We have 89	
previously reported stabilin-1 expression by HSEC, but not by resident liver macrophages 90	
(known as Kupffer cells), in normal human liver (10). Our observation of increased 91	
expression in a range of chronic inflammatory liver diseases led us to study whether 92	
stabilin-1 contributes to the progression of chronic liver disease and fibrogenesis.  93	
 94	
Results  95	
Stabilin-1 deficiency exacerbates liver fibrosis  96	
To investigate the functional role of stabilin-1 in liver injury and fibrosis we used two mouse 97	
models. In carbon tetrachloride (CCl4)-induced chronic liver injury a fibrogenic phase is 98	
followed by a spontaneous resolution phase (11)  and in mice fed a methionine choline 99	
deficient (MCD) diet hepatic steatosis is followed by inflammation and early fibrosis (12).  100	
Consistent with previous reports in stabilin-1-/- mice, sirius red positive fibres consistent with 101	
increased fibrogenesis were seen within the liver parenchyma which was otherwise normal 102	
(Fig.1A,B) (13). Following CCl4 administration, stabilin-1-/- mice developed a marked 103	
increase in hepatic scar formation compared with WT mice with features of bridging fibrosis 104	
(Fig.1A,B) and increased sirius red staining (SI Appendix Fig.S1A). Greater activation of 105	
fibrogenic pathways in stabilin-1-/- mice was confirmed by significantly increased 106	
accumulation of collagen I and III (Fig.1C,D, SI Appendix Fig.S1B,C).).  In order to study 107	
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the number and activation of fibrogenic cells at baseline and injury we compared the 108	
expression of glial fibrillary acidic protein (GFAP) as a constitutive marker of stellate cells to 109	
alpha smooth muscle actin (αSMA) and matrix metalloproteinase-2 (MMP-2) as markers of 110	
activated myofibroblasts (14, 15).  At baseline and throughout injury and resolution we 111	
detected increased GFAP expression in livers of stabilin-1-/- mice (Fig.1E-H).  In contrast 112	
αSMA and MMP-2 expression was significantly higher only during injury (Fig.1E-H, SI 113	
Appendix Fig.S1D,E) compared to WT mice.   114	
The role of stabilin-1 in the resolution of fibrosis was studied in mice during recovery after 115	
CCl4 injury. After four weeks of recovery, we noted persistent bridging fibrosis and 116	
increased collagen I and III transcription in stabilin-1-/- mice when compared to WT mice 117	
(Fig.1I,J).  Hydroxyproline quantification demonstrated an increase in collagen content in 118	
stabilin-1-/- mice at baseline comparable to that seen in WT mice after CCl4 administration 119	
(Fig.1K).   After four weeks of resolution, the hydroxyproline had reduced in WT mice but 120	
increased further in stabilin-1-/- mice (Fig.1K). We also noted that stabilin-1-/- mice 121	
demonstrated significantly increased ALT levels during liver injury (Fig.1L). To assess if 122	
elevated ALT levels were due to increased hepatocyte death or inefficient scavenging we 123	
co-stained for ALT and F4/80 and assessed markers of cell death.  We found increased co-124	
expression of ALT and F4/80 in WT mice compared to stabilin-1-/- mice, but no significant 125	
difference in levels of apoptosis and autophagy (SI Appendix Fig. S2 A-I). Histological 126	
assessment demonstrated minimal necrosis with no difference between WT and stabilin-1-/- 127	
mice at baseline or after 8 weeks of carbon tetrachloride (SI Appendix Fig. S2 J).  These 128	
findings suggest inefficient scavenging in stabilin-1-/- mice rather than increased cellular 129	
death.  130	
We also detected histologically more severe scarring in stabilin-1-/- MCD diet fed mice and 131	
significantly increased hydroxyproline levels compared to WT MCD diet fed mice, as well as, 132	
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higher, but not statistically significant, ALT levels (SI Appendix Fig.S3 A-E). Collectively 133	
these data show that in vivo there is an increased baseline fibrogenic response in stabilin-1-134	
/- mice, which is due to increased numbers of fibrogenic cells.  Fibrosis and scarring are 135	
enhanced upon injury, and the resolution phase is impaired in the absence of stabilin-1.  136	
Injury-dependent induction of stabilin-1 in hepatic macrophages  137	
We proceeded to study the cellular expression of stabilin-1 in normal and injured murine 138	
livers. In uninjured WT mice, stabilin-1 was restricted to CD31-positive sinusoidal 139	
endothelial cells and was absent from F4/80-positive Kupffer cells (SI Appendix Fig. S4A,B). 140	
In response to liver injury from either CCl4 or MCD diet we detected a subset of stabilin-1+ 141	
F4/80+ intrahepatic macrophages (SI Appendix Fig.S4C, S5A). Using αSMA as a cell 142	
lineage marker, we clearly demonstrated that myofibroblasts, which play a central role in 143	
liver fibrosis, do not express stabilin-1 during liver injury (SI appendix Fig. S4D, S5B).  144	
Analysis of chronic human liver disease demonstrated that CD31-positive sinusoidal 145	
endothelial cells expressed stabilin-1 whereas CD68-positive Kupffer cells within the 146	
sinusoids did not (SI Appendix Fig. S4E,F).  In contrast, stabilin-1+ macrophages were 147	
readily detected within the fibrous septa associated with the hepatic scar (SI Appendix 148	
Fig.S4G). Stabilin-1 was not detected on αSMA-positive myofibroblasts (SI Appendix Fig. 149	
S4H).  These studies demonstrate for the first time an intrahepatic subpopulation of stabilin-150	
1+ macrophages in liver injury.    151	
 152	
Stabilin-1 deficiency leads to a reduction of ceroid macrophages in liver injury.   153	
The presence of a population of stabilin-1+ macrophages in liver injury and previous 154	
findings that macrophages are critical to the development of fibrosis (16), led us to 155	
investigate whether an alteration in macrophage distribution or function contributes to the 156	
increased fibrosis in stabilin-1-/- mice.  Intrahepatic macrophage distribution and peripheral 157	
	 7	
blood monocyte numbers were comparable between uninjured WT and stabilin-1-/- mice 158	
(Fig.2A,B, SI Appendix Fig S9A). After CCl4 injury, WT mice demonstrated prominent 159	
aggregates of macrophages, which were not seen in the stabilin-1-/- animals (Fig.2A-C). 160	
These macrophage aggregates resembled ceroid-laden macrophages. Ceroid-laden 161	
macrophages contain lipid-like pigment deposits and have been previously described in 162	
experimental liver fibrosis but their pathological significance is unknown (17, 18).  163	
We hypothesized that stabilin-1 deficiency was associated with a reduction in ceroid-laden 164	
macrophage formation during liver injury and fibrosis.  To test this hypothesis, we used 165	
periodic acid-schiff diastase (PAS-D) staining to detect cytoplasmic ceroid accumulation.  166	
This confirmed the presence of large ceroid macrophages in WT mice (Fig.2D) that were 167	
largely absent in stabilin-1-/- animals (Fig.2D).  Interestingly, PAS-D also stains the fibrous 168	
scar and in the stabilin-1-/- mice the absence of ceroid-laden macrophages was associated 169	
with prominent fibrosis (Fig.2D).   170	
MDA is the most abundant aldehyde produced by lipid peroxidation and is highly reactive 171	
leading to the formation of MDA-modified LDL. This product of oxidative stress is taken up 172	
by macrophages and contributes to cytoplasmic ceroid accumulation (19).  In WT mice, 173	
prominent MDA-positive cells were clearly visible (Fig.2E), whereas minimal staining was 174	
detected in stabilin-1-/- mice (Fig.2E,F). 175	
A further well established property of ceroid accumulation is that the pigment, including 176	
MDA adducts, is autofluorescent (20). We identified prominent autofluorescent F4/80+ 177	
aggregates in WT mice which were greatly reduced in stabilin-1-/- mice in both CCl4- and 178	
MCD diet-induced liver injury (Fig.2G,H). We then showed that F4/80+ ceroid-laden 179	
macrophages in experimental liver injury in WT mice co-express stabilin-1 (Fig.2I). 180	
We used a thiobarbituric acid reactive substances (TBARS) assay to detect serum MDA 181	
and found similar levels in WT and stabilin-1-/- mice after CCl4 injury and MCD diet 182	
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suggesting that production of MDA is not reduced in stabilin-1 deficiency (Fig.2J). 183	
Proteomic analysis of baseline serum samples demonstrated increased levels of several 184	
proteins in the serum of stabilin-1-/- mice compared to WT mice (SI Appendix Table S1) 185	
several of which are related to oxidative stress. However we did not detect increased 186	
circulatory levels of pro-inflammatory or pro-fibrogenic cytokines such as TGFβ, PDGF A 187	
and B, in keeping with previous studies (13).    188	
Our findings prompted us to study the distribution of ceroid-laden macrophages in relation 189	
to sites and stage of fibrosis.  We detected ceroid-laden macrophages along the hepatic 190	
scar in WT mice (Fig.3A) whereas in stabilin-1 deficient animals, the absence of ceroid 191	
macrophages was associated with a dense network of collagen III in the hepatic scar 192	
(Fig.3B).  Further analysis of livers after 4 weeks resolution demonstrated the persistence 193	
of ceroid-laden macrophages in close proximity to residual hepatic scar in WT mice 194	
(Fig.3C). In contrast, ceroid-laden macrophages were not seen in stabilin-1-/- mice in which 195	
extensive collagen-rich scars persisted after 4 weeks of resolution (Fig.3D). Thus, 196	
collectively our data suggest that stabilin-1 on macrophages protects against liver fibrosis 197	
by taking up fibrogenic modified lipids.   198	
 199	
Stabilin-1 deficiency is associated with excess CCL3 production in liver tissue and 200	
stabilin-1 suppresses CCL3 expression in macrophages. 201	
To identify specific mediators of fibrogenesis in stabilin-1 deficiency, we used RNA-seq to 202	
compare the gene expression profile of liver tissue from WT and stabilin-1-/- mice.  A 203	
number of genes showed increased expression in stabilin-1-/- mice (SI Appendix Table S2) 204	
but the only established fibrogenic mediator which was increased was the chemokine CCL3 205	
(21, 22).    We validated our findings with qPCR of liver tissue and critically demonstrated 206	
that CCL3 was persistently elevated after four weeks of resolution in stabilin-1-/- mice 207	
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(Fig.4A).  In support of these findings we detected increased CCL3 protein in stabilin-1-/- 208	
mice which colocalised with hepatic macrophages (Fig. 4B-D).  209	
We investigated whether the pro-fibrogenic phenotype in livers of stabilin-1-/- mice was 210	
linked to ox-LDL uptake to form ceroid-laden macrophages.   We initially confirmed the 211	
presence of autofluorescent stabilin-1+ ceroid-laden macrophages in livers from patients 212	
with chronic liver diseases (SI Appendix Fig. S6A,B).  213	
As MDA-LDL is one of the most abundant products of lipid peroxidation and contributes to 214	
ceroid formation (23), we investigated whether stabilin-1 on human macrophages is 215	
involved in its uptake and degradation.  We isolated monocytes from human peripheral 216	
blood and stimulated their stabilin-1 expression in vitro (24).  After 2 hours of MDA-LDL 217	
incubation we were able to detect intracellular deposits of MDA-LDL completely co-218	
localised with stabilin-1 (SI Appendix Fig. S7A). Uptake of MDA-LDL was minimal in 219	
unstimulated monocytes which had low expression of stabilin-1 (SI Appendix Fig. S7B). A 220	
function blocking antibody to stabilin-1 led to the internalisation of stabilin-1 thereby 221	
inhibiting MDA-LDL uptake (Fig. 5A,B).   We also linked the scavenging function of stabilin-222	
1 positive macrophages to CCL3 expression by demonstrating a significant reduction in 223	
macrophage CCL3 transcription after MDA-LDL uptake compared to control (Fig. 5C).  We 224	
could reverse this effect using the function blocking antibody against stabilin-1 (Fig. 5D).  225	
These results suggest that stabilin-1 expression is critical for the uptake of MDA-LDL by 226	
macrophages, a process which also modulates macrophage-derived CCL3 secretion.   227	
 228	
Stabilin-1 deficiency is associated with a pro-inflammatory hepatic macrophage 229	
phenotype. 230	
To assess how stabilin-1 deficiency influenced macrophage phenotype we sorted 231	
macrophages from CCl4 treated livers. Analysis of WT hepatic macrophage populations 232	
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during liver injury demonstrated higher transcript expression of stabilin-1 in F4/80hi/CD11blo 233	
compared to the F4/80lo/CD11bhi population (SI Appendix Fig S8A).  The loss of stabilin-1 234	
led to higher expression of M1 markers CCL3 and TNFα in both F4/80hi/CD11blo and F4/80 235	
lo/CD11bhi subsets.  M2 marker MMP-9 was also elevated but Arginase-1 was reduced in 236	
the F4/80hi/CD11blo subset (SI Appendix Fig. S8B-E). This is in keeping with previous 237	
studies where defining macrophages through their polarisation to classical M1 or M2 238	
macrophages is unreliable in liver injury as M1/M2 markers can be expressed 239	
simultaneously by liver macrophages (25). 240	
Ramachandran et al. demonstrated that the CD11bhiLy6Clo monocyte-derived macrophage 241	
population increases significantly during fibrosis resolution and functions as the ‘restorative’ 242	
macrophage (25) leading us to compare populations of ‘pro-fibrotic’ CD11bhiLy6Chi and 243	
‘restorative’ CD11bhi Ly6Clo macrophages. Liver injury in both WT and stabilin-1-/- mice 244	
resulted in a predominance of Ly6Chi macrophages in the liver (SI Appendix Fig. S8F,G). 245	
During resolution there was a shift towards Ly6Clo macrophages in the WT group which 246	
was not seen in the stabilin-1-/- mice (SI Appendix Fig.S8H). Intrahepatic lymphocyte 247	
populations did not differ between WT and stabilin-1-/- mice after the injury or during 248	
resolution (SI Appendix Fig. S9B-K).  Collectively, these results demonstrate that the 249	
profibrogenic response in stabilin-1 deficiency is associated with a pro-inflammatory 250	
macrophage phenotype during injury.   251	
 252	
Deletion of stabilin-1 in myeloid cells is associated with a loss of ceroid-laden 253	
macrophages and exacerbated fibrosis.  254	
The preceding results suggest that stabilin-1 protects the liver from fibrosis by allowing 255	
macrophages to take up and remove pro-fibrogenic lipid peroxidation products and at the 256	
same time suppressing CCL3 production. To test this hypothesis in vivo we used Tie-2 Cre 257	
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and Lys2 Cre strains to generate cell-selective knockouts.  We have previously confirmed 258	
their selectivity and efficiency in knocking down stabilin-1 (26).  We have shown that in our 259	
Tie-2 Cre model stabilin-1 is absent from endothelium (ENDO stab-1-/-) but macrophage 260	
expression is maintained. In our Lys2 Cre model stabilin-1 is absent from the myeloid 261	
population (MACRO stab-1-/-). In practice this model is selective for macrophages, since 262	
neutrophils do not express stabilin-1 and therefore are unaffected by this knockout.  We 263	
confirmed this specificity in the livers of our cell selective strains at baseline and during liver 264	
injury (SI Appendix Fig. S10A,B). 265	
Fibrosis in ENDO stab-1-/- mice was comparable to WT mice in both CCl4 liver injury and 266	
MCD diet (SI Appendix Fig. S11A-C), whereas fibrogenesis was increased in MACRO stab-267	
1-/- animals (Fig.6A,B) with significantly more accumulation of collagen III associated with 268	
increased αSMA staining in MACRO stab-1-/- mice versus WT after CCl4 injury (Fig.6C-F).  269	
Fibrosis resolution was delayed in the MACRO stab-1-/- animals as demonstrated by 270	
persistently elevated transcript levels of αSMA and increased hydroxyproline staining and 271	
critically for our hypothesis we found persistent elevation of CCL3 compared to WT animals 272	
(Fig.6G-I) and increased serum ALT levels in response to CCl4 as seen in the full knockout 273	
(Fig.6J). We also detected significantly elevated hydroxyproline content in MACRO stab-1-/- 274	
mice compared to WT mice after MCD diet (SI Appendix Fig.S11D).  Thus the increased 275	
fibrosis in response to liver injury seen in the absence of stabilin-1 is predominantly 276	
mediated through stabilin-1 expressing macrophages.   277	
There were no detectable differences in the numbers of ceroid-laden macrophages in the 278	
livers of WT and ENDO stab-1-/- mice (SI Appendix Fig. S11E,F).  In contrast, very few 279	
ceroid-laden macrophages were seen in the livers of CCl4 treated MACRO stab-1-/- animals 280	
(SI Appendix Fig. S11E,F).  To further confirm the role of macrophage stabilin-1 in fibrosis 281	
resolution we undertook experiments similar in design to those described by 282	
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Ramachandran et al. (25). This consisted of a 4 week model of CCl4 liver injury performed 283	
in MACRO stab-1-/- and WT mice followed by adoptive transfer of wild type myeloid cell 284	
elements or vehicle control at 24 and 72 hours after the final injection of CCl4 followed by 285	
an analysis of fibrogenesis at 120 hours.  Transcription of fibrogenic markers and collagen 286	
III expression in liver tissue showed no differences between WT mice receiving myeloid 287	
cells or vehicle without cells (SI Appendix Fig S12A,D,F), whereas in the MACRO stab-1-/- 288	
there was a trend of reduced transcription in nearly all fibrogenic markers in mice receiving 289	
wild type myeloid cells (SI Appendix Fig.S12B).  We confirmed the presence of adoptively 290	
transferred Dsred+ myeloid cells within liver tissue at sites of collagen deposition (SI 291	
Appendix Fig. S12C).  Finally, we demonstrated a significant reduction in hepatic collagen 292	
III expression in MACRO stabilin-1-/- mice receiving wild type myeloid cells compared to 293	
vehicle control (SI Appendix Fig. 12E,F).  294	
 295	
Discussion 296	
This study reports a novel mechanism which involves a subset of stabilin-1+ macrophages 297	
found in both experimental and human liver injury which play a critical role in protecting 298	
against excessive fibrosis in response to oxidative stress.  Stabilin-1 deficiency led to an 299	
increase in hepatic CCL3 associated with the recruitment of GFAP+ fibroblasts and an 300	
increase in baseline hepatic fibrosis.  Using cell-specific knockout animals we were able to 301	
show that stabilin-1 mediates its effects by enabling macrophages to take up and clear 302	
fibrogenic oxidised lipids generated in response to liver injury. Stabilin-1 deficiency was 303	
associated with a marked reduction of ceroid-laden macrophages during liver injury. Ceroid-304	
laden macrophages are a well recognised pathological feature of liver injury but, to our 305	
knowledge, their contribution to liver fibrosis is unknown.  Ceroid contains modified 306	
lipoproteins (such as MDA-LDL) which are generated as a consequence of chronic 307	
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oxidative stress.  We found in both humans and mice that they are derived from a subset of 308	
macrophages, that upregulate stabilin-1.  The expression of stabilin-1 allows macrophages 309	
to take up and clear modified LDLs and in addition we show that this uptake suppresses the 310	
secretion of the pro-fibrogenic chemokine CCL3 resulting in reduced fibrosis and the 311	
promotion of scar resolution.  The highest levels of stabilin-1 were detected in the F4/80hi 312	
CD11blo population suggesting that tissue resident macrophages may upregulate stabilin-1 313	
during liver injury. Interestingly, stabilin-1 deficiency was associated with an inflammatory 314	
phenotype in both infiltrating monocytes and mature tissue resident macrophages. The 315	
therapeutic potential of stabilin-1+ macrophages was demonstrated by our finding that the 316	
adoptive transfer of wild type myeloid cells can promote resolution of fibrosis in stabilin-1 317	
deficiency.  These results suggest that macrophages which are stimulated or engineered to 318	
express high levels of stabilin-1 could be a potential cell therapy in fibrotic liver disease. In 319	
addition to its potential role in liver disease we suggest that stabilin-1 plays a role in tissue 320	
homeostasis by removing local products of low level oxidative stress.  This explains why 321	
increased fibrosis is seen in stabilin-1 deficient mice even in the absence of exogenous 322	
injury.  The liver is constantly exposed to bacterial products and xenobiotics from both the 323	
portal and systemic circulation and under normal conditions stabilin-1 on endothelium as 324	
well as on macrophages may allow the rapid removal of products of oxidative stress 325	
thereby preventing low level continuous injury and scarring. Whereas in response to liver 326	
injury, protection and resolution requires the involvement of stabilin-1+ macrophages.  327	
These findings describe a novel mechanism involved in the regulation of tissue fibrosis that 328	
allows efficient wound healing without destructive scarring in response to liver injury.  329	
  330	
Methods  331	
 332	
Animals 333	
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Stabilin-1 knockout mice and cell-specific mice were generated as previously described 334	
(26).  CAG-Dsred*MST1Nagy/J (stock 005441) were from the Jackson Laboratory. All animal 335	
studies were done in adherence with the rules and regulations of The Finnish Act on Animal 336	
Experimentation (62/2006), and accepted by the local Committee for Animal 337	
Experimentation (Animal licence number 5587/04.10.07/2014). 338	
Liver injury models 339	
 340	
Carbon tetrachloride (CCl4) injury model 341	
8-week-old mice were injected twice weekly for 8 weeks with either CCl4 (1.0 ml/kg CCl4 342	
diluted 1:3 in mineral oil, Sigma-Aldrich) or a mineral oil vehicle control. Animals were 343	
sacrificed 72 h after the final dose of CCl4 (27) or after a 4-week recovery period. 344	
 345	
Methionine Choline Deficient (MCD) Diet 346	
Mice were fed an MCD diet (Harlan laboratories TD90262) for 6 weeks ad libitum.  Control 347	
animals received normal chow for 6 weeks (27).   348	
 349	
Human tissue  350	
Tissue and blood samples from patients were obtained with written informed consent and 351	
with local ethics committee approval (LREC reference 06/Q2702/61 South Birmingham, 352	
Birmingham, UK and 04/Q2708/41 South Birmingham, Birmingham, UK). 353	
 354	
Statistical analysis , see  SI Appendix Supplementary methods. 355	
 356	
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Figure Legends 437	
 438	
 439	
Figure 1 440	
 441	
Stabilin-1 deficiency exacerbates fibrosis after CCl4 liver injury.  Wild-type (WT) and 442	
stabilin-1-deficient (stabilin-1-/-) mice were subjected to CCl4-induced liver injury: control 443	
(Oil); 8 week CCl4 injury (CCl4) and 4 week resolution after the CCl4 injury (Res). (A,B) 444	
Sirius red stainings in livers (n=4-5 in each group). (C-H) Collagen I, Collagen III 445	
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immunostainings stainings and GFAP/αSMA co-immunostainings and quantifications of 446	
liver sections (n=3-5 in each group).  (I) Sirius red staining from livers after resolution. (J) 447	
mRNA expression of Collagen I and Collagen III in livers. (K) Hydroxyproline determinations 448	
in liver samples and (L) serum alanine transaminase (ALT) levels. (for J-L n=5-6 mice in 449	
each group). Statistical significance was determined by unpaired t-test (G,H,J)) and 1-way 450	
ANOVA analysis, with a Tukey’s post-hoc multiple comparison test (K, L).  * P<0.05, ** 451	
P<0.005, ***P<0.001, ****P<0.0005.  Bars 200µm (A-D, I) Bars 50 µm (E, F)  452	
  453	
Figure 2 454	
 455	
Stabilin-1 deficiency is associated with a reduction of ceroid-laden macrophages 456	
during liver injury. (A,B) Staining of livers for F4/80 from WT and stabilin-1-/- mice in oil 457	
controls and CCl4 injury. Arrows indicate aggregates of F4/80+ cells. (C) Quantification of 458	
F4/80 positive area staining in WT and stabilin-1-/- mice in oil controls and CCl4 injury. (D) 459	
Periodic acid schiff-diastase (PAS-D) staining of livers from WT and stabilin-1-/- mice after 460	
CCl4 injury (black arrows highlight PAS-D positive cells and white arrows highlight areas of 461	
increased scar formation.  (E) Staining of livers for Malondialdehyde (MDA) from WT and 462	
stabilin-1-/- mice after CCl4 injury (F) Quantification of MDA positive area staining in WT and 463	
stabilin-1-/- mice after CCl4 injury.  (n=3-4 mice in each group) Representative high 464	
magnification fields in black box areas. (G) Autofluorescent ceroid aggregates (red) co-465	
stained with F4/80 (green) in WT and stabilin-1-/- mice after CCl4 injury. (H) Quantification of 466	
ceroid staining within F4/80+ cells in livers from WT and stabilin-1 -/- mice after CCl4 injury 467	
and MCD diet. (n=5 mice in each group). (I) Immunofluorescent staining of livers from WT 468	
mice after CCl4 injury double stained for F4/80 (green), stabilin-1 (orange) and 469	
autofluorescent ceroid (red). (J) Measurement of serum MDA levels using TBARS assay in 470	
WT and stabilin-1-/- mice after CCl4 injury and MCD diet-induced injury (n=4 mice in each 471	
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group). Statistical significance was determined by unpaired t-test (C,F,H,J) * P<0.05, ** 472	
P<0.005, ***P<0.001. Bars 100 µm (A,B), 200 µm (D,E), 50 µm (G), 10 µm (I).  473	
 474	
Figure 3 475	
Loss of ceroid-laden macrophages is associated with exacerbation of hepatic 476	
scarring. 477	
(A,B) Immunofluorescent staining of WT and stabilin-1-/- mice after CCl4 injury and (C,D) 4 478	
weeks resolution for F4/80+ cells (green) and Collagen III (red).  Right hand panels are 479	
magnification of inset boxes in left hand panels (arrows highlight ceroid-laden 480	
macrophages). Bars 200 µm (A-D). 481	
 482	
 483	
Figure 4 484	
Stabilin-1 deficiency is associated with increased intrahepatic CCL3.    Wild-type (WT) 485	
and stabilin-1-deficient (stab-1-/-) mice were subjected to CCl4-induced liver injury: control 486	
(Oil); 8 week CCl4 injury (CCl4) and 4 week resolution after the CCl4 injury (Res). (A) mRNA 487	
expression of CCL3 in livers (n=5-7 mice in each group). (B) Immunofluorescent staining of 488	
WT and stabilin-1-/- mice in control (Oil) livers of F4/80+ cells (red) and CCL3 (green) and 489	
(C) quantification of CCL3 staining (n=3 in each group for B,C). (D) High magnification 490	
image of co-staining for F4/80+ cells (red) and CCL3 (green) from stabilin-1-deficient 491	
(stabilin-1-/-) liver. Statistical significance was determined by unpaired t-test (A,C) *P<0.05, 492	
** P<0.005, Bars 50 µm (B), 5 µm (D). 493	
 494	
Figure 5 495	
Stabilin-1 suppresses CCL3 expression during Malondialdehyde-LDL uptake by 496	
macrophages. 497	
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(A) Immunofluorescent staining of IL-4/Dex cultured human monocytes pre-treated with 498	
isotype control and or (B) Stabilin-1 function blocking antibody (3-372) followed by 499	
incubation with MDA-LDL (10 µg/ml) for 2 h. Representative images from three separate 500	
cell isolates.  (C) Comparison of mRNA expression of CCL3 in IL-4/Dex cultured human 501	
monocytes (control) and those exposed to MDA-LDL for 24h. (D) Comparison of mRNA 502	
expression of CCL3 in IL-4/Dex cultured human monocytes exposed to MDA-LDL for 503	
24hours, pre incubated with IgG1 antibody (control; 10 µg/ml) or 3-372 antibody (Stab-1 504	
blocking antibody; 10 µg/ml) (n=3 independent experiments).  Statistical significance was 505	
determined by a paired t-test. *P<0.05, ***P<0.005. Bar 10 µm (A,B), 506	
 507	
Figure 6 508	
 509	
Stabilin-1 deficiency on macrophages leads to increased ECM deposition. Wild-type 510	
(WT) and macrophage stabilin-1-deficient (MACRO stab-1-/-) mice were subjected to (A-H) 511	
CCl4-induced liver injury: control (Oil); 8 week CCl4 injury (CCl4) and 4 week resolution after 512	
the CCl4 injury (Res). (A,B) Sirius red stainings in livers. (C-F) Collagen I, Collagen III and 513	
αSMA immunostainings and quantifications of liver sections. (G) mRNA expression of 514	
αSMA and CCL3 in livers, (for A-G n=4-6 mice in each group). (H) Hydroxyproline 515	
determinations in liver samples (n=5-6 mice in each group) and serum alanine 516	
transaminase (ALT) levels (n=4-5 mice in each group). Statistical significance was 517	
determined by unpaired t-test (E) and 1-way ANOVA analysis, with a Tukey’s post-hoc 518	
multiple comparison test (G, H).    * P<0.05, ***P<0.001. Bars 200 µm (A-D). Bars 50 µm 519	
(F). 520	
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